
ã¹ããŒããšçŸæ£
éåâ¢ã¹ããŒãÃå ç§,medicina,57(7):2020ãèªãã§ãã¢ã¹ãªãŒããæé·æã®ã¢ã¹ãªãŒããæ°ãä»ããªããã°ãªããªãçŸæ£ã«ã€ããŠå匷ããŸããã
ã¢ã¹ãªãŒãã ãã§ãªããå¹ åºãäžä»£ã®ã¹ããŒããã³ãã¹ããŒããŠãŒãã³ã«åããå 容ã§çãæ²¢å±±ãšãªã£ãŠããŸããããäžã§ãã¢ã¹ãªãŒããšå¯Ÿé¢ããæ©äŒãããã°æ°ãä»ããŠã¿ãŠã¿ãããªãšããçç¶ãããã€ããã£ãã®ã§ãè¬å€åž«ãšããŠå¯Ÿé¢ãããšããæ³å®ããŠå°ãèããŠã¿ãŸããã
è¬å€åž«ãšããŠã®ããããã«ã€ããŠèãã
ãæç« ãèªã¿é²ããŠã¿ãŠãã
ã¹ããŒãçŸæ£ã«é¢ããéšåã¯ã
ããã¬ãŒãã³ã°ããé£äºããäŒé€ããã¡ã³ã¿ã«ã
ãšãã£ãéšåã§ããããã®èŠçŽ ã®è³ªãäœäžãããšã¹ããŒãå ç§ç³»çŸæ£ã«ã€ãªãããšãã£ãå 容ã§ãŸãšãŸããŸãã
é¢ããé åãšããŠã
ããæŽåœ¢å€ç§ãããã婊人ç§ããããå
ç§ããããã¹ããŒãæ é€å£«ãã
ãšããwordã¯åºãŠããŸããããè¬å€åž«ããšããã¯ãŒãã¯ä»è·çš®ãããªããªãã§ãŠããŸããïŒãããããŠãâã¢ã³ãããŒãã³ã°âããšããèšèã¯åºãŠããããªïŒã
ã¹ããŒããã¡ãŒãã·ã¹ãããããã¹ããŒãè¬å€åž«ïŒã¹ããŒãè¬å€ïŒã®æ¹ããããããããŠããã®ããªïŒ
ãªããªãé£ããã§ããããã¢ã³ãããŒãã³ã°ã¯è¬å€åž«ãŸããããšãªãããã«è¬å€åž«ãã§ããããšãã¢ããŒã«ããŠããå¿ èŠæ§ãæããŸããã
ç¹ã«æ°ã«ãªã£ãçŸæ£
â ãã¹ããŒãè²§è¡
â ãéåèªçºæ§æ°ç®¡æ¯åçž®ïŒEIBïŒ
â ãæçµåšæãšããã©ãŒãã³ã¹ã/ãç¡æçµ
â ãã¹ããŒãã¡ã³ã¿ã«ïŒãã€ç ïŒ
â ããªãŒããŒãã¬ãŒãã³ã°çå矀ïŒOTSïŒ
â ããã®ä»
ã¢ã¹ãªãŒãã¯ãã®é«ãå¿èºæ©èœã身äœèœåã«ãã£ãŠçç¶ããã¹ã¯ãããèªèŠçç¶ãç®ç«ã¡ã«ããããšããããã
âãå蚺ãé
ãããããâãå
ç§çã¡ãã£ã«ã«ãã§ãã¯ãå¿
èŠ
ãŸããåçš®çŸæ£ã®èšºæã«ã¯ãé€å€çŸæ£ã®éå¥ãå¿
èŠãšãªãã
â ãã¹ããŒãè²§è¡ããæç çã5ã25%Â
è²§è¡ãã¹ããŒãããã£ãŠãã人ã®äžã§ãããŸã§ã¡ãžã£ãŒãªçŸæ£ã ãšã¯ç¥ããŸããã§ãããæ é€ã®éšåãšããããŠã¿ãŠãããããšæããŸãã
ãªãè²§è¡ã«ãªãã®ãïŒ
ïŒïŒééèŠå¢å
ïŒïŒéæåäžè¶³ãåžåäœäž
ïŒïŒéåªå€±å¢å
ïŒïŒæº¶è¡ã«é¢é£ãããã®
ïŒïŒééèŠå¢å
ïŒïŒéæåäžè¶³ãåžåäœäž
ãã»åžåäœäžïŒåè¢ã«è¡æµãåªå
ãããè
žç®¡ã®è¡æµãå¶éãåãã
ãïŒéåã«ããéã®åžåãäœäž
ãã»ããã·ãžã³ã«ããåžåé害
ãïŒéååŸã®éåžåãäœäž
éåæã®ã°ãªã³ãŒã²ã³è²¯èµã«ããIL-6ã®éååŸã®å¢å ãç°ãªãããšã瀺ãããŠããïŒ
â
ççæ§ãµã€ãã«ã€ã³IL -6 ã®å¢å
â
ããã·ãžã³(éã®åã蟌ã¿ãæå¶ãã)çºçŸå¢å
å©çšå¯èœãšãã«ã®ãŒãäžè¶³ããŠãããšãéãååã«ãã£ãŠãHbã®åæã¯é²ã¿ã«ãããããéã®ã¿ã§ãªãé£äºå šäœãèŠçŽããŠããå¿ èŠããããŸãã
ãåèè³æã
ïŒãéååã®ååãªãšãã«ã®ãŒæåããçã°ãªã³ãŒã²ã³ãç¶æããããšã«ãã£ãŠéåèªçºæ§ã®IL-6ãæžå°ãããïŒNutritional Interventions and the IL-6 Response to Exercise.FASEB J,31(9):3719-3728,2017.)
ãããèãããšãè²§è¡ã«ãããŠãéåã ãã§ãªãéååã»äžã»åŸã®ã°ãªã³ãŒã²ã³æåã®å€§åããããããŸãïŒå€§å¡è£œè¬ããŒã ããŒãžããïŒã
詳ããã¯ãã¡ãã®ãµã€ããã芧ãã ããã
ãŒãé£äºã®POINTïŒïŒãïŒ
é床ã®ãã¬ãŒãã³ã°ãè¡ããšéã®æ¶èãå¢å ããŸãããããã«èŠãã£ãåã ãé£äºããéãæåïŒ15mgïœ18mg/æ¥éæåæšå¥šïŒããªããã°éæ¬ ä¹ãšãªãïŒéèŠãšäŸçµŠã®ãã©ã³ã¹ãä¿ã€ïŒããŸãéã ãã®æåã§ã¯äžååã§æåã«ããªãŒãéååã»äžã»åŸã®ã°ãªã³ãŒã²ã³ã®æåã倧åã
ãšãã«ã®ãŒã«é¢ããŠã¯æ é€ã®éšåã§ãèšèŒããããŸãããç¹ã«å¥³æ§ã§åé¡ã«ãªããšãã«ã®ãŒäžè¶³ã®ããã§ãããç·æ§ã§ãã¿ãããããã§ãã
REDãŒSïŒRelative Energy Deficiency in SportïŒ
çžå¯Ÿçãªãšãã«ã®ãŒäžè¶³
https://www.waseda.jp/prj-female-ath/problem/red_s/
ïŒïŒéåªå€±å¢å
ã女æ§ã¢ã¹ãªãŒãïŒæçµã«ãã倱è¡
ãçºæ±ããã®éåªå€±ã2ã3LïŒæ¥ã®çºæ±ã§1mgïŒæ¥ã®éåªå€±ã«ãªã
ãè
žç®¡ããã®åŸ®çްãªåºè¡
ïŒïŒæº¶è¡ã«é¢é£ãããã®
ãè¶³åºãžã®ç¹°ãè¿ãè¡æãåå ã§ç©ççãªèµ€è¡çç Žå£ã亢é²ãã
ã©ããªçç¶ãã¿ãããã®ãïŒ
æ¯åããåæžãããŸããåŠæ æãæç²åŽæ§ãé éæ
ïŒâ»ä»£è¡šçãªãã®ãæ¯åãïŒ
éåžžã®è²§è¡ãšå€ãããªãããããã©ãŒãã³ã¹ã®äœäžã«ã€ãªãã
â»é·è·é¢ç«¶æãé§
äŒãªã©è¡ã£ãŠããæ¹ã§å€ãã
ãèšèã§èšèŒãããšãã®ãããªçç¶ãªãã§ãããå®éã«ãããã£ã人ã«äŒã£ãããšãç¡ãã®ã§ãäœãšãªãã€ã¡ãŒãžãæ¹§ããŸããããŸããéåžžã®è²§è¡ã§ããã°åŸã ã«Hbãäœäžããå Žåãããã«å°ããã€èº«äœãæ £ããŠããŸãèªèŠçç¶ãšããŠãæ°ã¥ãã«ããã®ãäžè¬çã ãšæããŸãã
æ¡è¡ä»¥å€ã«Hbæšå®å€ã枬å®ããæ©åšããããããã¢ã¹ãªãŒãã§ã¯äœ¿çšããŠããæ¹ãããããã§ãããã¡ãŒã«ãŒåžæå°å£²äŸ¡æ Œã398,000åãšé«ãçŸå®çã§ã¯ãããŸããã
ãã¯ããèªèŠçç¶ãšããŠã¯æ°ã¥ãã«ãããã®ãªã®ã§ãæ®æ®µãšéãæ¯åããã¹ã©ã³ããæãããç é¢ãåèšºãæ¡è¡ãããŠãããïŒHbããã§ãªãã³ïŒãšããæµããããã®ããªãšæããŸãã
ïœãHbïŒãã¢ã°ããã³ïŒæ£åžžå€ãïœ
ç·æ§ 13 g/dLãå¥³æ§ 12 g/dL
ïŒã¢ã¹ãªãŒãã®ç®å®ïŒãç·ã14g/dLã女ã12.5g/dLãïŒããé«ãïŒ
ãã§ãªãã³ãäžéå€ãç·30ÎŒlïŒmlã女20 ÎŒlïŒml
äžçªãããªãã®ããèªåã§è²§è¡ã ãšå€æããŠéåãéå°ã«æåããŠããŸãããšã§ãã倧åŠå¥³åéžäžé·è·é¢éžæã«ããããµããªã¡ã³ãã®æåç¶æ³ã«ã€ããŠèª¿æ»ããå ±å*ã§ã¯ãå
šäœã®69%ãéãµããªã¡ã³ããæåããŠãããã¢ããé
ž(39%)ãæ¬¡ãã§ãã¿ãã³Cããã«ããã¿ãã³ããããã€ã³ãã«ã«ã·ãŠã ãšç¶ããŠãããæä¹
åãã€ããããã®éãµããªã®æåãå€ããªããã¡ãªããšãäºæ³ãããŸãã
ãåèè³æã
ïŒã倧åŠå¥³åéžäžé·è·é¢éžæã«ããããµããªã¡ã³ãã®æåç¶æ³.äœåç§åŠ,52 (5):631-638,2003
ééå°ã«ãªããšã©ããã£ãçç¶ãã§ãã®ãïŒ
éãéå°ã«ãªããšãèèãå¿èãããèãªã©ã«éãæ²çããŠèåšé害ãåŒãèµ·ãããŸãã
ãèèïŒãã©ã³ã¹ã¢ãããŒãŒäžæãèç·ç¶åãè硬å€
ãå¿èïŒåçž®æ©èœäœäžã巊宀é§åºçïŒLVEFïŒãäœäž
ãããèïŒÎ²çްèç Žå£ã«äŒŽãèç³èœäœäžãç³å°¿ç
ïŒæ¥ãããéåã®èçšäžéé
ç·æ§ã50mgã女æ§ã40mg
åºæ¬çã«ã¯ããã§ãªãã³ãFeãªã©ãåºæºå€å
ã®å Žåãéåã远å ã§æåããŠãããã©ãŒãã³ã¹ãäžæããããšã¯ãããŸããã®ã§ãããããšã¯äœããããŸããã
ãã¹ããŒãè²§è¡ãâå°ãŸãšãâãèªåãªãäœããã§ãã¯ãããïŒã
â æä¹ ç³»ã®ã¹ããŒããããŠãã人ã«ãæ¯åããããã©ãŒãã³ã¹äœäžã確èª
â¡ãµããªã¡ã³ãã®æåã®æç¡ã確èªïŒéãµããªã«æ³šæïŒ
â¢ç é¢ã§ã®æ¡è¡ãããããïŒHb,ãã§ãªãã³ã§èšºæïŒ
â£éãäžè¶³ããä»çµã¿ãæåŸã«ã€ãããŠé£äºã®æ¯æ£ãæ é€å£«ãž
â ãéåèªçºæ§åæ¯ããæç çïŒ5ã20ïŒ ã
ïŒEIBïŒexercise induced bronchoconstrictionïŒ
éåèªçºæ§æ°ç®¡æ¯åçž®ïŒéåã§èªçºãããå³åœã
åæ¯ã®æç¡ã«ãããããçºçããããã³ã³ãããŒã«äžååãªåæ¯æ£è ã§ã®çºççãé«ã
ã©ãããŠãããã®ãïŒ
éåã«ããææ°éãå¢ãã
â也ç¥ãã倧éã®ç©ºæ°ã«ããæ°é衚é¢ã®æ°Žåã奪ããã
âæ°éè¡šé¢æ¶²ïŒairway surface liquid:ASLïŒã髿µžéå§ã«ãªã
POINTïŒïŒ ãæ¹¿åºŠããææ°éå¢å ã
ãå京ãªãªã³ããã¯ããã³ã¢ãããªãªã³ããã¯ã«åå ããã¢ã¹ãªãŒãã察象ãšããç ç©¶ã§ã¯ã忝ã®TUEç³è«ã«æãããé¢é£ããã¹ããŒãã¯æ°Žæ³³ïŒïŒïŒïŒ
ïŒããµã€ã¯ãªã³ã°ïŒïŒïŒïŒ
ïŒããã©ã€ã¢ã¹ãã³ïŒïŒïŒïŒ
ïŒãäºçš®ç«¶æïŒïŒïŒïŒ
ïŒãããŒãç«¶æïŒïŒïŒ
ïŒã§ããã察ç
§çã«ãäœæããã§ã³ã·ã³ã°ãã»ãŒãªã³ã°ãªã©ãæä¹
åãå¿
èŠãšããªãçš®ç®ã®ã¢ã¹ãªãŒãã®åæ¯ã®æç
çã¯5ïŒ
æªæºã§ãã£ããšãããŠããŸã*ã
ãåèè³æã
ïŒãPrevalence and characteristics of asthma in the aquatic disciplines.J Allergy Clin Immunol,136(3):588-94,2015
ãããã¿ãŠãããšãææ°éãå¢ããæä¹ ç³»ã®ã¹ããŒãã§èµ·ããããããæ¹¿åºŠãèæ ®ãããšãå€ã®ã¹ããŒããããå¬ã®ã¹ããŒãã®æ¹ãããã«èµ·ãããããããšãäºæ³ãããŸãã
察å¿ïŒ
éåååŸã§ã®ããŒã¯ãããŒæž¬å®ïŒåŒæ°æå€§æµéïŒ1ç§éã«åãåºãæ¯ã®éïŒ
ã»éååã®çæéäœçšåβ2åºæ¿è¬ïŒSABAïŒ
ã»é·æéäœçšåβ2åºæ¿è¬ïŒLABAïŒ
ã»åžå
¥ã¹ããã€ãè¬ïŒICSïŒ
ã»LTåå®¹äœæ®æè¬ïŒLTRAïŒ
ã»éååã®è¥æºçްèå®å®åè¬ã€ã³ã¿ãŒã«ãæã³ãªã³è¬åžå
¥
çŠæ¢ç©è³ªã«ã¯æ³šæ
忝ã®åžå ¥è¬ã«ã€ããŠã¯ãã®NOTEã§ãæžããŠãŸããβïŒäœçšè¬ã®äžã«ã¯çŠæ¢ç©è³ªã«è©²åœãããã®ããããŸãã
ãéåèªçºæ§åæ¯ãâå°ãŸãšãâãèªåãªãäœããã§ãã¯ãããïŒã
â ãŸãã¯åæ¯ã®ã³ã³ãããŒã«ç¶æïŒçç¶æ¹ååŸã宿çãªåžå ¥æšå¥šïŒ
â¡æä¹ ç³»ã®ã¹ããŒãã§ã¯æ³šæ
â¢å€ããå¬ã«æ³šæ
â£ãã¯ãçŠæ¢ç©è³ªã«è©²åœããè¬ã§ã¯ãªãããšã確èªïŒ
â ãæçµåšæãšããã©ãŒãã³ã¹ã/ãç¡æçµ
女æ§ã®åé¡ãšãªãã®ã§ãç·æ§ã§ããç§ã«ã¯è¬å€åž«ãšããŠãèžã¿èŸŒã¿ã«ããé åã§ã¯ãããŸããã女æ§ã¢ã¹ãªãŒãã®ç«¶æèœåã®åäžã®ããã«ã¯ãšãŠã倧åãªéšåã ãšæããŠããŸãã
ïœãåé¡ãšãªãçç¶ãïœ
ãPMS(æçµåçå矀)ã
æµ®è
«ãã€ã©ã€ã©ãè
°çãä¹³æ¿çãé çãäžè
¹éšçãèèããäœéå¢å ã飿¬²äº¢é²ãç æ°ãªã©
ãæçµå°é£çã
åå®®å
èã§ç£çãããããã¹ã¿ã°ã©ã³ãžã³ã®éå°ç£çã§çã¿ã䌎ã
æçµå°é£çã«ã¯ãåå®®å
èçãåå®®çè
«ãšãã£ãçŸæ£ãé ããŠããå Žåããããããå蚺ããŠãã¡ããšèšºæããŠãããããšã倧åã§ãã
äžæçèª¿æŽæ³ïŒæ¬¡åã®æçµã ãã調æŽãããäžçšéãã«ã
ç¶ç¶çèª¿æŽæ³ïŒå¹ŽéãéããŠç¶ç¶çã«æçµã調æŽãããäœçšéãã«ã
çç¶ãèªããã¢ã¹ãªãŒãã«ã¯ãäžæçèª¿æŽæ³ã§ã¯ãªãç¶ç¶çèª¿æŽæ³ãå§ãã
ãããããéã«ã¯æçšãäžæ¢ãããªã©æ³šæãå¿ èŠãªå Žåãããã
ïŒãã«ã«é¢ããŠã¯ã¢ã³ãããŒãã³ã°çã«ã¯åé¡ãããŸããïŒ
OCïŒoral contraceptives)ãLEPïŒlow dose estrogen progestinïŒã«ããè¡æ ãªã¹ã¯
ãPMSãæçµå°é£çã®çç¶ç·©åã«ããéåããã©ãŒãã³ã¹ãåäžããããšãèŠåçãªæçµåšæãåŸãããããšã«ããã³ã³ãã£ã·ã§ã³ã®ã³ã³ãããŒã«ã容æã«ãªãããšãªã©ãèãããšã女æ§ã¢ã¹ãªãŒãã«ã¯LEPã®æçšãæšå¥šãããŸããããã¯ãOCãLEPã«ã€ããŠã€ã³ã¿ãŒãããæ€çŽ¢ãããšã倪ããããããè¡æ ããšãã£ãã¯ãŒããã©ãããŠãåºãŠããŠæçšãè¿·ããã£ãããšãªã£ãŠããŸããŸãã
倪ãããããšèšãããã®ã¯ãã£ãšæã®è©±ã®ããã§ãæçšéå§ãããã«ã¢ã³ã®ç¶æ ãå®å®ãããŸã§ïŒãæçšåºŠèŠãããšèšãããŠããŸãããæåã®ïŒïœïŒãæã«äººã«ãã£ãŠã¿ããããããã¿ããäœéå¢å ãšã¿ãããããšãããããã§ããæçšãç¶ããããšã«ããå ã«æ»ããšèšãããŠããã®ã§ããã¯åé¡ãªãããã§ãã
è¡æ ã®ãªã¹ã¯ã¯ïŒãšãããšãFDAïŒã¢ã¡ãªã«é£åå»è¬åå±ïŒã®ãµã€ãã§
FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone
ïŒããã¹ãã¬ãã³ãå«ãé¿åŠè¬ãæçšããŠãã女æ§ã«ãããè¡æ ã®ãªã¹ã¯ã«é¢ããæ
å ±ïŒ
ïŒå¹Žéã10,000人ïŒïŒäžäººïŒã®å¥³æ§ã远跡ããçµæãè¡æ ãçºçããå¯èœæ§
ãæ®éã®äººããããïŒãïŒïœïŒäººãããïŒ0.01ïœ0.05%ïŒ
ããã«æçšè ãããïŒãïŒïœïŒäººãããïŒ0.03ïœ0.09%ïŒ
ãåŠåš äžãããããïŒãïŒïœïŒïŒäººããïŒ0.05ïœ0.2%ïŒ
ãåºç£åŸïŒïŒé±éãïŒãïŒïŒïœïŒïŒäººãïŒ0.4ïœ0.65%ïŒ
æ®éã®äººãšæ¯ã¹ãŠãªã¹ã¯ã¯äžãããŸãããããã»ã©é«ããšãèšãããåŠå©Šããã«æ¯ã¹ããšããªãäœã確çã ãšããããšãããããŸããïŒãããã£ããããªã¹ã¯ãäžåãã§ããããšããçµè«ïŒ
ãã ãããã¡ããšè¡æ çã«å¯Ÿããæ³šæã¯å¿ èŠã§ãçºçææã«ã€ããŠã¯æçšéå§ïŒãæãŸã§ã«å€ãã¿ãããïŒæçšéå§ 3 ã«æãŸã§ãæãçºçé »åºŠãé«ãã以åŸäœäžããæçšéå§ãã 1 幎åãéããããããã»ãŒãã©ããŒã«ãªãïŒãããç¹ã«æçšåæã®å®æçãªå蚺ã¯å€§åã§ãã
ãŸããããã«ããå€ç§çæ²»çãé·æå®éã匷ããããå Žåã«ãè¡æ ã®ãªã¹ã¯ã«æ³šæããå¿ èŠããããŸãã
ãæçµåšæãšããã©ãŒãã³ã¹ãâå°ãŸãšãâãèªåãªãäœããã§ãã¯ãããïŒã
â 倪ããèèããè¡æ ãªã©OC,LEPã®èª€è§£ãè§£ã
â¡è²§è¡ãâãæçµå°é£çã®æµããããåŸã
â¢ãããããå Žåã®æ³šæç¹ãäŒããŠãã
ç¡æçµãå šèº«ã«åœ±é¿ãã
ã¢ã¹ãªãŒãã®ç¡æçµïŒç¶çºæ§ç¡æçµ
éåæ§ç¡æçµïŒé床ã®éåè² è·ã«ãã身äœçã»ç²Ÿç¥çã¹ãã¬ã¹ãåå ã§çããŸããïŒ3ã¶æä»¥äžæçµã忢ããŠããç¶æ
ïŒ
é·æçã«ã¯ã骚ç²é¬çãå¿è¡ç®¡ã€ãã³ãã®ãªã¹ã¯ãäžæãããšèšãããŠããŸãã
â ãã¢ã¹ãªãŒãã®ãã€ç
ãã£ãªã¢ã§ã®æªæãç«¶æã§ã®å€±æçµéšããã£ãªã¢ã®åŒéãçŒçãå人ã¹ããŒãããã£ãããšãªã£ãŠçºçããå ŽåããããŸãã
ããæ²»çæ³ãã
âãèªç¥è¡åçæ³
âãéåçæ³
âãè¬ç©çæ³
ïŒãã€ç æ²»çã¬ã€ãã©ã€ã³ã§ã¯è»œçäŸã«å¯ŸããŠäœµçšã«ããéåçæ³ã®æšå¥šãåããŠèšèŒãããã
ïŒé±äžå以äžãäžç床以äžã®éåãæšå¥šããããšããŠããããåæã«äžå®ããèŠè§£ã¯ãªããšãè¿°ã¹ãããŠããã
ïŒéåããã©ãŒãã³ã¹äœäžã«çŽæ¥é¢ãããããªäœæ¥ãæããè¬ç©çæ³ã«æ¶æ¥µçãšãªãåŸåãããã
ãæãã€è¬ïŒæ¶ååšçç¶ãäœéå¢å ãåŸç
ããã³ãŸãžã¢ãŒãã³ç³»è¬ç©ïŒé®éäœçšãçåŒç·©äœçš
ãã¢ã¹ãªãŒãã®ãã€ç ãâå°ãŸãšãâãèªåãªãäœããã§ãã¯ãããïŒã
â ããã©ãŒãã³ã¹ã«åœ±é¿ãäžããå¯äœçšã«ããè¬ç©çæ³ãäžæ¢ããªãããã«æ¯æŽãã
â¡ã¢ã³ãããŒãã³ã°ã«æµè§Šããè¬ç©ãšããŠäžæ¢ç¥çµåºæ¿è¬ãÎ²é®æè¬ãªã©ããäžéšã§ã¿ããããããªã®ã§ã䜿çšè¬å€æ¯ã«ãã§ãã¯ãã
â ããªãŒããŒãã¬ãŒãã³ã°çå矀ïŒOTSïŒããæç çïŒ5ã64ïŒ ã
éå°ãªãã¬ãŒãã³ã°ã®ç¹°ãè¿ãïŒè¶ å埩æãåŸ ããã«é«åŒ·åºŠã®ãã¬ãŒãã³ã°ãç¶ããããšïŒã§ããã©ãŒãã³ã¹ãäœäžãã容æã«å埩ããªããªã£ãæ ¢æ§ç²åŽç¶æ ãšå®çŸ©ãããŠããŸãã
å°ãªããšã3ã4é±é以äžã®äŒé€ããšã£ãŠãããã©ãŒãã³ã¹ãæ»ããªã
ãäž»èšŽãæ°åé害ã䌎ãåå äžæã®ããã©ãŒãã³ã¹äœäž
ãã®ä»çç¶ïŒæãã€æ°åãææ¬²æžéã飿¬²äœäžãäžç ãçŠç¥æãäžå®ãéäžå°é£ãåæžãæ¯åããå
šèº«åŠæ æãç«ã¡ããã¿ãè¡å§äžæãçèçãç²åŽå埩é
å»¶ãææææ§
OTSã®çç¶ã¯å€å²ã«æž¡ãé£ããã§ããã
確ç«ãããèšºæææšã¯ãªãããåèææšã¯ãã
ãè¡äžä¹³é
žå€ãOTSïŒæå€§ä¹³é
žå€ãéåžžæã«æ¯ã¹ãŠäœäžãã
ãå¿ææ°ãOTSïŒæå€§å¿ææ°ãäœäžããããã¬ãŒãã³ã°åâ¢äžã§ã¢ãã¿ãªã³ã°
ãPOMS æ°åã¹ã³ã¢
ç·åçã«å€æãæ©æçºèŠ
ãŸããæ®µéãèžãã§æªåããŠããã®ã§ããã®éäžæ®µéã§çºèŠããã
æ¥æ§ç²åŽAFïŒå埩æéãïŒæ¥ïœæ°æ¥ïŒ
â
æ©èœæ§ãªãŒããŒãªãŒãã³ã°FORïŒå埩æéãæ°æ¥ïœæ°é±éïŒ
â
éæ©èœæ§ãªãŒããŒãªãŒãã³ã°NFORïŒå埩æéãæ°é±éïœæ°ãæïŒ
â
OTSïŒå埩æéãæ°ãæä»¥äžïŒ
ããªãŒããŒãã¬ãŒãã³ã°çå矀ãâå°ãŸãšãâãèªåãªãäœããã§ãã¯ãããïŒã
â æ¡è¡ææšããããããçã£ããå蚺å§å¥šããŸã第äž
â¡æ®µéãããã®ã§ãæ©ã段éã§æ°ã¥ããŠãããããããã«æ®æ®µãšã®éããæãåã
â ããã®ä»
ãã®ã»ãã«ããã¢ã¹ãªãŒããæ©ãŸããçç¶ã¯ãããããšããããã§ãããã®ãããã¯ç°¡åã«ãŸãšããã®ã§ãèŠããŠãããŠä»åŸã«æŽ»ãããã°ãšæããŸãã
ïŒïŒèè ¹çãéææ§è žçå矀
ïŒïŒïŒïŒèµ°ã£ãŠããæã«ãè
¹ãçããªãïŒèè
¹ç
ETAP(exercise-related transient abdominal pain)
ããã¯èªåãéåããŠããŠãããŸã«ãããŸããæºåéåãååã§ãªãã£ããæ¥ã«åãããããå Žåãé£äºã»æ°Žåããšã£ãŠããã«åããå Žåãªã©ã«èµ·ãããããããªæ°ãããŸãããã¯ã£ãããšããåå ã¯ããã£ãŠããªãããã§ãã
ã察çã
éåéå§2æéåã®é£äºæåããã€ããŒãããã¯ãçé
žãæ§ãã
è
¹èãæšªéèã®åºæ¿ãæžãããããäœå¹¹ãã¬ãŒãã³ã°ããã
ãæ¹åçã
çããªã£ãåŽã䌞ã°ãããã«äœãåãäºã§è
¹è
å
ã«ã¹ããŒã¹ãã§ããçã¿ãæ¹åããå¯èœæ§ããã
ãã®æ¹åçã¯ä»åºŠèµ·ãããæ¯éãã£ãŠã¿ãããšæããŸãã
ïŒïŒïŒïŒéææ§è žçå矀
詊ååãªã©ãç·åŒµããŠãè
¹ãçããªã
ã¹ãã¬ã¹ããã¬ãã·ã£ãŒâè³ãããå¯è
ç®è³ªåºæ¿ãã«ã¢ã³æŸåºãã«ã¢ã³ããæŸåºããããããè
žã®åãã«å€åããããããšèšãããŠããŸãã
é·è·é¢éžäžéžæã察象ãšãã調æ»ã§ã¯ã
æäŸ¿ç¶æ
ãšç«¶ææçžŸãé¢ãã£ãŠãããšæããšåçãã人ã¯70ïŒ
ã«ãåãã§ããŸãã
ããã©ãŒãã³ã¹ã«ã©ãã»ã©åœ±é¿ãããã¯åãããŸãããã圱é¿ããå¯èœæ§ãããã°å蚺ããããããçç¶ã®äžã€ã§ãã
éææ§è žçå矀ïŒIBSïŒã¬ã€ãã©ã€ã³ã§ããšããã³ã¹ã¬ãã«Aã«è©²åœããè¬ã¯çŠæ¢ç©è³ªã«è©²åœããŠããªãã®ãïŒ
âã©ã¢ã»ããã³ïŒã€ãªããŒÂ®ïŒïŒè©²åœãªã
âããªã«ã«ããã£ã«CaïŒããªãã«Â®ãã³ããã«Â®ïŒïŒè©²åœãªã
âäžç°ç³»æãã€è¬ãSSRIïŒè©²åœãªã
ãã®ä»ããšããã³ã¹ã¬ãã«Bã«è©²åœããè¬ãæ°å€ããããããå®éã®äœ¿çšè¬å€ã«å¿ããŠè©²åœã®æç¡ã倿ããå¿ èŠããããŸãã
ïŒïŒããŸãç«ã¡ããã¿
ãåå ã
éåæãéååŸã ãšãè²§è¡ãè±æ°Žãäœé
žçŽ ãéå§è¬ïŒÎ²é®æè¬ãªã©ïŒã®æçšãªã©
ãã¬ãŒãã³ã°æãç«¶æäŒåã ãšãèªåŸç¥çµã®ç°åžžïŒäº€æç¥çµãå¯äº€æç¥çµã®ãã©ã³ã¹ã®ä¹±ãïŒ
ïŒïŒçè²ãè¡å°¿
å€ãã®å Žåãè¡å°¿ããã¢ã°ããã³å°¿ã¯äžéæ§
æç¶ãããããªãå蚺ãå¿
èŠãšãªã£ãŠããŸãã
éååŸã®æº¶è¡ïŒè¡å°¿ããã¢ã°ããã³å°¿ãããªã°ããã³å°¿
ç¹ã«ããªã°ããã³å°¿ïŒæšªçŽçãèè§£ãããŠèµ·ããïŒã¯æ³šæãå¿
èŠ
ãåå ã
ã»éå匷床ãéåæéã®åŒ·ããé·ãã«ããè
èã®ç³žçäœã®ééæ§äº¢é²ãèµ€è¡çãå°¿çŽ°ç®¡ãžææ³ããã
ã»ã©ã³ãã³ã°ããžã£ã³ããèªè»¢è»ç«¶æãªã©èè±ãžã®æ¯åãéæ¥è¡æã«ããèè±åºè¡
ã»ã³ã³ã¿ã¯ãã¹ããŒãåŸã®èåšæå·





